Brno University Hospital
Brno, 62500, Czechia
Location status: Recruiting
NCT Number: NCT05891873
Intensive and critical care in the intensive care unit (ICU) is often associated with ICU delirium and post-ICU dementia, regardless of the nature of the primary disease or insult. Optimal practical management of ICU delirium including its screening, prevention, and treatment, is an integral part of the current recommendations for optimal ICU care, but there are large gaps in the knowledge about the optimal and most effective prevention and treatment of this complication. Information on the actual implementation of these recommendations in the Czech Republic is lacking. The diagnosis of delirium is particularly challenging in neurointensive care patients (due to overlap with symptoms of primary brain lesions) and in a paediatric population. A complementary multicentre observational 4-year follow-up study, performed in an adult neurointensive/critical care stroke cohort and in a paediatric intensive/critical care cohort in centres following currently recommended preventive measures (Delusion-deep-cz) will investigate the incidence of ICU delirium and post-ICU dementia and their modifiable and non-modifiable predisposing and precipitating risk factors. Objectives are to determine the optimal methods for diagnostic screening of these complications and for the differential diagnosis of conditions mimicking delirium (non-convulsive epileptic state) or symptoms hindering its diagnosis (aphasia), and to study the association between sleep disturbances and ICU delirium to verify the role of sleep in the pathophysiology of delirium.
Interested in participating?
Request InfoAll sexes
Observational
Brno, 62500, Czechia
Location status: Recruiting
Design
Recruitment (groups)
General working hypotheses
Outcomes Primary outcomes
Objectives
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
People with aphasia will be examined by a skilled speech therapist.
Patients with positive delirium will undergo EEG examination. 10-min native EEG.
Time frame: up to 14 days after admission
assessed by experienced neuro-intensivist
Time frame: up to 10 weeks
Time frame: 6 months
Time frame: 6 months
Time frame: up to 10 weeks and after 6 months
the higher score, the worse result meaning cognitive impairment and non-independence
Contact information is provided by the study sponsor or research team.
Josef Bednařík, prof. MD, CSc.
CONTACT
Lucia Bakošová, MD
CONTACT
Masaryk University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07114458
Brain Diseases, Central Nervous System Diseases
Hamburg, Free and Hanseatic City of Hamburg, Germany
View Trial DetailsNCT05127265
Confusion, Critical Illness
Gainesville, Florida, United States
View Trial DetailsNCT06192615
Confusion, Delirium
Los Angeles, California, United States
View Trial DetailsNCT07641153
Confusion, Delirium
Houston, Texas, United States
View Trial Details